AlphaQuest’s Pacific Biosciences PACB Stock Holding History

AlphaQuest’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,109	Closed	-$168K	–	1759
2023 Q4	$168K	Buy	+17,109	New	+$140K	0.04%	660

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

AlphaQuest's PACB Position: Q1 2024 in Review

AlphaQuest sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 17,109 shares — an estimated $168K sold.

AlphaQuest first reported a position in PACB in Q4 2023 and held it in 1 quarter. The position peaked at $168K in Q4 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

AlphaQuest reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
AlphaQuest sold 17,109 Pacific Biosciences shares in Q1 2024, an estimated $168K.
AlphaQuest first reported a position in Pacific Biosciences in Q4 2023 and held it in 1 quarter.
AlphaQuest's Pacific Biosciences position peaked at $168K in Q4 2023.
268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on AlphaQuest's 13F filing for Q1 2024, filed 9 May 2024.